Henry M. Sobell completed his studies at Brooklyn Technical High School (1948-1952), Columbia College (1952-1956), and the University of Virginia School of Medicine (1956-1960). Instead of practicing clinical medicine, he then went to the Massachusetts Institute of Technology (MIT) to join Professor Alexander Rich in the Department of Biology (1960-1965), where, as a Helen Hay Whitney Postdoctoral Fellow, he learned the technique of single crystal X-ray analysis. He then joined the Chemistry Department at the University of Rochester, having been subsequently jointly appointed to both the Chemistry and Molecular Biophysics departments (the latter at the University of Rochester School of Medicine and Dentistry), becoming a full tenured Professor in both departments (1965-1993).He is now retired and living in the Adirondacks in New York, USA.
Dr. Osorio is a innovative businessman with an distinct entrepreneurial mindset concentrated in adding value on the areas of Biotechnology (mRNA), Reprogramming & Regenerative Medicine for translational use in humans and a variety of clinical applications aimed for both the private and the public health sectors. He is the CEO of RegenerAge Clinic and RegenerAge Beauty. VP and Clinical Developer for Bioquark, Inc., CCO at Reanima Advance Biosciences Project. President at Dr. Jois an anti-aging, beauty, and cosmetic products endorsement company. VP and Chairman of the WAMS Americas Division. Earned MD degree at Westhill University. Diplomate in aesthetic medicine (UAG), Advance Fellow by the ABAARM, visiting scholar at UNC at Chapel Hill in Dermatology. Fellow in Stem Cell Medicine by the A4M and USF, Business Diplomate at ECA, enrolled Master on Health Sciences at Victoria University. Has appeared on several occasions on International media, some of his latest broadcast appearances are CNN español, TV Azteca, Excelsior Newspaper, Medicable, PharmaBoard Room, and Podcasts among others. His public appearances as a speaker at the 2018 RAADfest (San Diego), 3rd International Conference on Molecular Medicine and Diagnostics (Dubai), Global Academic Business Forum on Tissue Engineering and Regenerative Medicine (Baltimore), Second International Congress on mHealth (Shiraz), 6th International Conference on Tissue Engineering and Regenerative Medicine (S.F), 11th World Congress on Cell & Tissue Science (Tokyo), 17th International Conference on Neurology and Neuroscience (Toronto), 9th International Conference & Exhibition on Tissue Science and Regenerative Medicine (Las Vegas) among others, makes him a pioneer on the Regenerative+Reprogramming Medicine Field. His passion for football, brought as a result the Dr.Jois Foundation A.C aimed at helping those American football athletes who have sustained injury get another chance through the Regenerative & Reprogramming Medicine.
Regenerative Medicine, Anti-Aging Medicine.
Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, graduated from Astrakhan State Medical University and was awarded with MD. In 1985, maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, Moscow, Russia. In 2001, finished the PostDoc Research Fellowship Program and maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1985 through 1987, worked at Inst of Med Enzymology, USSR Academy of Medical Sciences. From 1987 through 1989, was a senior Researcher, Koltzov Inst of Developmental Biology, USSR Academy of Sciences. From 1989 through 1995, was being a Head of the Lab of Clinical Immunology and Immunobiotechnology, Helmholtz Eye Research Inst in Moscow. From 1995 through 2004, was being a Chairman of the Dept for Clinical Immunology, Moscow Clinical Research Institute (MONIKI) and the Immunologist-in-Chief of the Moscow Regional Ministry of Health. In 1993-1996, was an Executice Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. Dr Suchkov is a Co-Supervisor over the Russian-American Agreement on scientific and clinical collaboration in the field of ocular immunology between Russian Academy of Sciences and National Institutes of Health (NIH); in 1991-1995 – a member of The Reciprocal Exchange Fellowship Program between Russian Immunological Society and British Society for Immunology. Dr Suchkov is a member of the Editorial Boards of many international journals including EPMA Journal (Springer, Brussels) and “Personalized Medicine Universe” (Elsevier, Japan). Dr Sergey Suchkov, MD, PhD Director, Center for Personalized Medicine and Professor, Department of Pathology, Sechenov University, Chair, Department for Translational Medicine, Moscow Engineering Physical Institute (MEPhI), Professor, Dept for Immunology, A.I.Evdokimov Moscow State University of Medicine & Dentistry, Moscow, Russia Member, New York Academy of Sciences, NY, USA Secretary General, UCC (United Cultural Convention), Cambridge, UK Member, EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; Member, ISPM (International Society for Personalized Medicine), Tokyo, Japan; Member, PMC (Personalized Medicine Coalition), Washington, USA; Member, American Chemical Society (ACS), USA; Member, American Heart Association (AHA), USA; Secretary General, UCC (United Cultural Convention), Cambridge, UK
Dr.R.Selvakumar completed his Ph.D in Biotechnology from Bharathiar University India and currently working as Associate Professor in Nanobiotechnology, at PSG Institute of Advanced Studies, Coimbatore, India. His area of interest are Bone and cartilage Tissue Engineering, Biomaterials-biomolecule interaction for Tissue Engineering application. He is a recipient of several international fellowships like, Endeavour research fellowship, Australia, WARI fellowship, USA and Blaustein fellowship, Israel and national fellowships like CSIR-SRF from Govt. of India. He has more 56 publications that have been cited over 523 times. His H- index is 13. He has filed three patents and has transferred his technology on Design, fabrication & method of producing micro, meso and nanoporous three dimensional (3D) scaffolds for Tissue Engineering using removable needle technology, to Intellectual Ventures, USA. He is a active reviewer in various journals.
MSc. José Manuel Baena, research associate "Advanced therapies: differentiation, regeneration and cancer" IBIMER, CIBM, Universidad de Granada. Founder of BRECA Health Care, pioneer in 3D printed custom made implants for orthopedic surgery, and REGEMAT 3D, the first Spanish bioprinting company. Expert in innovation, business development, and internationalization, lecturer in some business schools, he is passionate about biomedicine and technology. In his free time, he is also a researcher at the Biopathology and Regenerative Medicine Institute (IBIMER).
Bio-medicine, Tissue Engineering, Bio-materials, Bone tissue regeneration and Stem cell therapy.
For 25 years, he has been developing gene and cell therapy using non-human primates, immune-tolerant mice and rats to protect against the side effects of radiation. He collaborates with clinicians to develop strategies for treatment of patients after radiotherapy overexposures. He has participated in the first establishment of proof of concept of the therapeutic efficacy of Mesenchymal stem cells (MSCs) for the treatment of hematopoietic deficit, radiodermatitis and over dosages of radiotherapy. He has contributed to the first reported correction of deficient hematopoiesis in patients (graft failure and aplastic anemia) thanks to intravenous injection of MSCs restoring the bone marrow microenvironment, mandatory to sustain hematopoiesis after total body irradiation. He is scientific investigator of Clinical phase II trial evaluating the efficacy of systemic MSC injections for the treatment of severe and chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy (NCT02814864Hirsch Index 26.
Regenerative medicine, Cell therapy, Scaffold and Radiotherapy